Saturday 17 October 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
In the quarter to June 2026, EPS grew 38.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
1.55
0.04
−2.52%
Follow SKYE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (233.87%) | (167.97%) | (126.85%) | (94.31%) |
+8 more TTM periods Free account |
|
| (159.80%) | (136.16%) | (110.66%) | (83.39%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
9,362.64% | (642.85%) | (282.63%) | (157.19%) | |
Free Cash Flow per Share |
(7.71) | (8.56) | (8.61) | (8.31) | |
Free Cash Flow |
(38.27) | (42.43) | (42.71) | (41.20) | |
Capital Expenditures |
0.54 | — | 0.35 | 0.26 | |
| Other line items | |||||
Cash ROIC |
(400.04%) | (162.46%) | (93.33%) | (60.46%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
1,300.64 | 440.88 | — | — | |
Operating CF/Net income |
0.77 | 0.74 | 0.77 | 0.81 | |
Depreciation/Fixed assets |
20.96 | 0.95 | 0.80 | 0.69 | |
Capex/Depreciation |
0.78 | 0.00 | 0.49 | 0.37 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.82) | (8.56) | (8.69) | (8.36) | |
Capex per Share |
0.11 | 0.00 | 0.07 | 0.05 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates